Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
81.38
+2.48 (+3.14%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
806,319
Open
79.62
Bid (Size)
79.00 (100)
Ask (Size)
84.00 (200)
Prev. Close
78.90
Today's Range
79.09 - 82.83
52wk Range
55.17 - 170.87
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally
↗
February 26, 2026
MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend.
Via
The Motley Fool
Topics
Energy
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?
↗
February 26, 2026
AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data analytics platform.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Performance
YTD
-38.5%
-38.5%
1 Month
-15.2%
-15.2%
3 Month
-51.3%
-51.3%
6 Month
-36.9%
-36.9%
1 Year
-17.9%
-17.9%
More News
Read More
GeneDx to Participate in Upcoming Investor Conferences
February 25, 2026
From
GeneDx
Via
Business Wire
GeneDx (WGS) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlook
↗
February 23, 2026
Via
Chartmill
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
February 23, 2026
From
GeneDx
Via
Business Wire
Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge
↗
February 16, 2026
Via
The Motley Fool
Topics
Energy
Regulatory Compliance
Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets
↗
February 16, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year
↗
February 16, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy
↗
February 16, 2026
Via
The Motley Fool
Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares
↗
February 16, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health
February 11, 2026
From
GeneDx
Via
Business Wire
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
February 03, 2026
From
GeneDx
Via
Business Wire
The Great Rotation: Small-Caps Stand Tall as AI Exhaustion Triggers Tech Rout
January 29, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
The Great Rotation of 2026: Why Wall Street is Abandoning Big Tech for Main Street Small Caps
January 28, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Great AI Pivot: From Massive Build-Out to the Era of Operational ROI
January 27, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
The Great Rotation: Wall Street’s ‘Earnings Handoff’ Moves from Silicon Valley to Main Street
January 26, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Earnings
The Great Rotation: Small-Caps Set to Outpace ‘Magnificent 7’ in Historic Earnings Handoff
January 26, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 25, 2026
Via
The Motley Fool
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 24, 2026
Via
The Motley Fool
The Great Rotation of 2026: Why Wall Street is Betting Big on the Russell 2000
January 22, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights
January 15, 2026
From
Halper Sadeh LLC
Via
Business Wire
The Great Rotation: Small-Cap Stocks Surge in Early 2026 as Market Leadership Broadens
January 13, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Great Rotation: Small-Caps Log Longest Winning Streak Against S&P 500 Since 2019
January 12, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
January 12, 2026
From
GeneDx
Via
Business Wire
Frequently Asked Questions
Is GeneDx Holdings Corp. - Class A Common Stock publicly traded?
Yes, GeneDx Holdings Corp. - Class A Common Stock is publicly traded.
What exchange does GeneDx Holdings Corp. - Class A Common Stock trade on?
GeneDx Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeneDx Holdings Corp. - Class A Common Stock?
The ticker symbol for GeneDx Holdings Corp. - Class A Common Stock is WGS on the Nasdaq Stock Market
What is the current price of GeneDx Holdings Corp. - Class A Common Stock?
The current price of GeneDx Holdings Corp. - Class A Common Stock is 81.38
When was GeneDx Holdings Corp. - Class A Common Stock last traded?
The last trade of GeneDx Holdings Corp. - Class A Common Stock was at 02/26/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.